RxDoctor Payments Data

Eileen Zhuang

Critical Care Medicine · Baltimore, MDNPI 1881080745

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by GSK at 54.5% of the total.

$1,025in general payments, 2019–2025

Across 41 payments — averaging $25.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$558
  • Novartis$73
  • Grifols USA, LLC$69
  • Amgen$57
  • Insmed, Inc.$54
  • Boehringer Ingelheim$52
  • plus $162 from 6 others

What the payments were for

  • Food & beverage$1,025100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,025 in reported general payments places this provider in the 75th percentile of 231 critical care medicine providers in Maryland.

See all critical care medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$108,286
Medicare patients
322
Services billed
890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter102$116,467
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$15,846
Breo ElliptaFluticasone/Vilanterol13$13,254
Incruse ElliptaUmeclidinium Bromide15$8,361
Albuterol Sulfate HfaAlbuterol Sulfate82$4,004
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$3,147
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,414
Montelukast Sodium22$373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$558$153,927156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 231 critical care medicine providers in Maryland.

Other critical care medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →